Company Information

    Spero Therapeutics was founded on January 2013. The company is based in Cambridge, MA, USA . The number of employees in Spero Therapeutics is less than 50. Spero therapeutics is developing first in class therapeutics for treatment of gram-negative infections.
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Spero Therapeutics has received 8 rounds of venture funding. The total funding amount is around $256.4M.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Spero Therapeutics - Blog

                          • PASTEUR Act Reintroduced – A Bold, Potentially Transformative Approach to Addressing the Threat of Antimicrobial Resistance

                          • By: Melissa Stundick, Senior Vice President, Business Development  June 16, 2021 PASTEUR Act Reintroduced – A Bold, Potentially Transformative Approach to Addressing the Threat of Antimicrobial Resistance Yesterday an important step forward occurred for all of us looking to combat antimicrobial resistance (AMR).  The Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act, otherwise known as the PASTEUR […]The post PASTEUR Act Reintroduced – A Bold, Potentially Transformative Approach to Addressing the Threat of Antimicrobial Resistance appeared first on Spero.
                          • COVID-19 Has Made Hospital Avoidance a Critical Component of Good Care

                          • By: Nayiri Baljian and Jennifer Reese  August 11, 2020 COVID-19 Has Made Hospital Avoidance a Critical Component of Good Care Since Spero began developing oral tebipenem for the treatment of cUTI, we have been consistent in advocating the importance of keeping patients who do not require hospitalization out of the hospital. Hospital avoidance has been a […]The post COVID-19 Has Made Hospital Avoidance a Critical Component of Good Care appeared first on Spero.
                          • SPR720: Listening to patients, clinicians and regulators, and advancing forward

                          • By: Troy Lister PhD, Sue Stokes, PhD and David Melnick, MD  June 11, 2020 SPR720: Listening to patients, clinicians and regulators, and advancing forward Recently, Spero announced a positive meeting with the FDA that we believe supports our plans to advance SPR720, our novel oral agent for treatment of NTM disease, towards a Phase 2a clinical […]The post SPR720: Listening to patients, clinicians and regulators, and advancing forward appeared first on Spero.
                          • Evidence Matters: Importance of Tebipenem HBr Oral-Only Trial Design for Clinical Utility and Commercial Uptake Potential

                          • By: Cristina Larkin and David Melnick, MD  February 26th, 2020 Spero is developing tebipenem HBr to provide patients with complicated urinary tract infections (cUTI), the physicians that treat them, and the payors that support their care treatment options outside of the hospital, thus potentially reducing millions of days of hospitalization and billions of dollars in unnecessary […]The post Evidence Matters: Importance of Tebipenem HBr Oral-Only Trial Design for Clinical Utility and Commercial Uptake Potential appeared first on Spero.
                          • Beyond the headlines: Why we are excited about our pipeline and the future for patients needing effective treatments for infections

                          • By: Ankit Mahadevia, MD – CEO of Spero Therapeutics January 9th, 2020 Against a steady drumbeat of alarmist rhetoric in the lay press regarding infectious disease, at Spero we remain focused on developing our first-in-class pipeline of oral agents to treat what we believe to be the two largest infectious disease market opportunities:  complicated urinary tract infections […]The post Beyond the headlines: Why we are excited about our pipeline and the future for patients needing effective treatments for infections appeared first on Spero.
                          • New Options for Patients: New Preliminary Clinical Data on SPR720 and Our Stepwise Plan to Explore the Broad Potential of SPR720 in NTM

                          • By:  David Melnick, MD – Chief Medical Officer of Spero Therapeutics December 5, 2019 We recently announced positive preliminary, blinded data on SPR720 that we believe supports the further development of SPR720 as an oral agent for the treatment of NTM pulmonary disease.  The data released: Identify a dose range for SPR720 to explore in […]The post New Options for Patients: New Preliminary Clinical Data on SPR720 and Our Stepwise Plan to Explore the Broad Potential of SPR720 in NTM appeared first on Spero.

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *